Ascending cholangitis is the most life-threatening biliary emergency — it occurs when bacteria (usually E. coli, Klebsiella, Enterococcus) colonise the biliary tree in the setting of biliary obstruction (usually a CBD stone, but also from benign or malignant strictures). The raised biliary pressure from obstruction forces bacteria through the tight junctions into the hepatic sinusoids, causing bacteraemia and rapid progression to septic shock. Charcot's Triad (RUQ pain + jaundice + fever) is present in approximately 70% of cholangitis cases. Reynolds' Pentad (Charcot's + confusion + hypotension) indicates severe cholangitis with septic shock — mortality without intervention is approximately 50%. The treatment priorities: (1) IV broad-spectrum antibiotics immediately (do not wait for cultures — piperacillin-tazobactam or ciprofloxacin + metronidazole as alternatives); (2) aggressive fluid resuscitation; (3) urgent biliary decompression by ERCP within 12-24 hours — this is the definitive treatment. GPs who see a jaundiced febrile patient with RUQ pain must call 999, not refer to outpatient gastroenterology.

The Murphy's sign is one of the most clinically useful bedside tests in acute RUQ pain assessment — it differentiates acute cholecystitis (Murphy's positive) from biliary colic (Murphy's negative). The technique: place the examining fingers beneath the right costal margin at the mid-clavicular line (position the gallbladder fossa), then ask the patient to take a deep breath. A positive Murphy's sign: the patient abruptly arrests inspiration due to pain as the descending diaphragm forces the inflamed gallbladder against the examining fingers. This is distinct from simple RUQ tenderness — the key feature is the inspiratory arrest (the patient physically cannot complete the breath due to pain). Sensitivity approximately 65-70%, specificity approximately 87%. In obese patients and in cholecystitis with pericholecystic fluid or abscess, Murphy's may be negative — USS is the definitive investigation. USS Murphy's (USS probe placed directly over gallbladder + patient asked to breathe deeply) has superior sensitivity to clinical Murphy's.

The Courvoisier's Law (or sign) is a valuable clinical rule that applies specifically to painless jaundice with a palpable gallbladder — the law states: in a patient with jaundice and a palpable, non-tender gallbladder, the cause is unlikely to be gallstones. This counterintuitive principle is explained by pathophysiology: in gallstone-related obstructive jaundice, the gallbladder has undergone chronic inflammatory changes from recurrent stone impaction, making it thickened, fibrotic, and unable to distend. In pancreatic head carcinoma (or cholangiocarcinoma), the gallbladder is healthy and compliant — when the CBD is obstructed by extrinsic tumour compression, bile backs up and the gallbladder distends, becoming palpable. Therefore: palpable non-tender gallbladder + jaundice = malignancy (usually pancreatic head cancer or periampullary tumour) until proved otherwise. Action: 2WW hepatobiliary cancer referral + CT pancreas + CA 19-9 + CEA.

Gallstone pancreatitis has a specific management consideration that distinguishes it from other causes of acute pancreatitis — ERCP with sphincterotomy is indicated in gallstone pancreatitis when: (1) there is concurrent cholangitis (urgent within 12-24h); (2) there is persistent biliary obstruction (bilirubin not falling, CBD dilated, clinical deterioration — within 48-72h); (3) severe pancreatitis without rapid clinical improvement (within 72h). In mild gallstone pancreatitis with spontaneous clinical improvement (falling amylase, resolving symptoms, improving inflammatory markers), ERCP is not required during the admission — the CBD stone has passed. However, all patients with gallstone pancreatitis require cholecystectomy during the same admission (before discharge), or within 2 weeks for mild cases, to prevent recurrence. Deferring cholecystectomy after gallstone pancreatitis has a 12-30% recurrence rate within 30 days of discharge — this is entirely preventable with same-admission cholecystectomy.

The timing of cholecystectomy after acute cholecystitis has been definitively settled by the ACDC trial and CHOCOLATE trial — both demonstrated that early laparoscopic cholecystectomy within 72 hours of acute cholecystitis is safer and more cost-effective than delayed interval cholecystectomy (6-12 weeks after medical treatment). Early surgery: significantly lower total complication rate, shorter total hospital stay, no bile duct injury increase, avoids the 15-20% rate of early recurrence during the waiting period for interval surgery. Tokyo Guidelines 2018 recommend early cholecystectomy within 72 hours for Grade I-II acute cholecystitis in fit patients. GPs writing referral letters for acute cholecystitis should specify the Tokyo Grade and request early cholecystectomy, not simply 'surgical review.' The historical practice of treating acute cholecystitis medically, discharging home, and booking an interval cholecystectomy is now considered suboptimal by current evidence.

The diclofenac superiority over opioids for biliary colic is a well-established evidence base that is underutilised in UK primary care — a Cochrane systematic review (Colli et al., 2012) comparing NSAIDs with opioids for acute biliary colic showed that NSAIDs (diclofenac, ketorolac, indomethacin) provide equivalent or superior pain relief and significantly reduce the risk of progression to acute cholecystitis compared to opioids. The mechanism: prostaglandins amplify biliary tract smooth muscle contraction and sensitise pain receptors in the gallbladder wall — NSAIDs inhibit prostaglandin synthesis, thereby both reducing the biliary spasm and reducing the inflammatory cascade that leads to cholecystitis. Opioids increase sphincter of Oddi pressure (which may theoretically worsen biliary obstruction) and do not have anti-inflammatory effects. In practice: GP practices should stock diclofenac 75 mg IM for acute biliary colic episodes presenting to the surgery — it provides faster, better analgesia and reduces hospital admission rate.

The post-cholecystectomy diarrhoea from bile acid malabsorption is a common and underdiagnosed complication affecting approximately 10-15% of patients after cholecystectomy — the gallbladder normally acts as a reservoir for bile, releasing concentrated bile into the duodenum in response to meals (mediated by CCK). After cholecystectomy, bile flows continuously from the liver into the duodenum in a slow trickle rather than in meal-stimulated boluses. This results in: (1) insufficient bile concentration for fat emulsification (fatty food intolerance — steatorrhoea); and (2) excess bile acids reaching the colon (bile acid diarrhea type 3 — BAD3), where they stimulate water and electrolyte secretion, causing watery diarrhoea. Treatment: colestyramine (bile acid sequestrant) 4g before meals binds excess bile acids in the bowel, reducing colonic stimulation. SeHCAT scan (not always available) confirms bile acid malabsorption. Clinical diagnosis often sufficient — trial of colestyramine for 4-6 weeks.

The ursodeoxycholic acid (UDCA) for gallstone dissolution represents a pharmacological approach that has very limited clinical application — UDCA (8-10 mg/kg/day, divided doses) can dissolve small (≤5 mm), radiolucent (cholesterol) gallstones in a functioning gallbladder, but the dissolution rate is low (approximately 40-60% at 1-2 years), recurrence after stopping UDCA is high (approximately 50% at 5 years), and it has no efficacy against pigment stones (approximately 20% of all gallstones) or calcified stones. NICE does not recommend UDCA as routine treatment for symptomatic gallstones. Its main current clinical applications: (1) after bariatric surgery (prevention of new stone formation — 6 months); (2) in patients with very small (<5 mm) cholesterol stones who are unfit for surgery; (3) primary biliary cholangitis (where it slows progression). GPs prescribing UDCA for gallstone dissolution should discuss the low success rate and high recurrence, and should ensure cholecystectomy has been considered.

The retained common bile duct stone after cholecystectomy is the most common late biliary complication, occurring in approximately 1-3% of post-cholecystectomy patients — small CBD stones may be present at the time of laparoscopic cholecystectomy but not identified (the CBD is not routinely explored during elective cholecystectomy unless intraoperative cholangiography is performed or preoperative MRCP shows CBD stones). Presentation: typically within weeks to months post-cholecystectomy — jaundice, RUQ pain, fever (if cholangitis develops). Investigation: LFTs (elevated ALP/bilirubin/GGT) + USS (dilated CBD >6 mm) + MRCP (confirms stone). Treatment: ERCP + sphincterotomy + stone extraction. GPs should consider retained CBD stone in any post-cholecystectomy patient presenting with RUQ symptoms or abnormal LFTs — refer urgently to hepatobiliary team.